University of North Carolina

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

Tuesday, April 18, 2017

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, have signed a collaboration agreement with StrideBio, a U.S.-based company developing novel AAV vectors for in vivo gene delivery applications.

[Read More]

Millennials accelerate seismic shift in clinical operations

Saturday, April 1, 2017

As the largest age demographic in the U.S., Millennials are dramatically reshaping the clinical research industry. Millennials have high expectations about technology, convenience and data transparency—traits that are catalyzing a trend toward decentralization and prompting industry leaders to carve out new roles in clinical trial management.

[Read More]

NIH funds research network focused on HIV-infected youth

Monday, September 26, 2016

The NIH has awarded funding for a research network devoted to the health and well-being of adolescents and young adults with HIV or at risk for HIV infection. The awards, up to $24 million in 2016, provide for three research centers and a data coordinating center that will make up the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).

[Read More]

C4 Therapeutics completes core scientific leadership team

Wednesday, September 7, 2016

C4 Therapeutics (C4T) has announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D., as senior vice president of Translational Sciences and Alliance Management, Stewart Fisher, Ph.D., as senior vice president of Discovery Sciences, Tim Heffernan, Ph.D., as senior vice president of Biology, and Christopher Nasveschuk, Ph.D., as vice president of Chemistry.

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

Grants to help target genomic variants

Wednesday, September 23, 2015

Six new grants from the National Institutes of Health will support researchers to develop new computational approaches for searching among millions of genomic variants to find those that make a difference in disease susceptibility or in other traits. The awards are for three years each, and total about $13 million, pending the availability of funds. They are administered by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute, both parts of NIH.

[Read More]